Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 4 (2007), Issue 11 (November)

1. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes.
   Oncogene, 26(50): 7158-62. [Abstract] [Full-text]
2. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma.
   Int J Cancer, 122(1): 91-9. [Abstract] [Full-text]
3. Genetic variants and haplotype analyses of the ZBRK1/ZNF350 gene in high-risk non BRCA1/2 French Canadian breast and ovarian cancer families.
   Int J Cancer, 122(1): 108-16. [Abstract] [Full-text]
4. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer.
   Int J Cancer, 122(1): 170-6. [Abstract] [Full-text]
5. Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer.
   Cancer Res, 67(21): 10389-96. [Abstract] [Full-text]
6. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis.
   Cancer Res, 67(21): 10117-22. [Abstract] [Full-text]
7. A novel technique for the enrichment of primary ovarian cancer cells.
   Am J Obstet Gynecol, 197(5): 507.e1-5. [Abstract] [Full-text]
8. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.
   Cancer Res, 67(22): 10976-83. [Abstract] [Full-text]
9. Endostatin binding to ovarian cancer cells inhibits peritoneal attachment and dissemination.
   Cancer Res, 67(22): 10813-22. [Abstract] [Full-text]
10. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
    J Clin Oncol, 25(33): 5180-6. [Abstract] [Full-text]
11. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
    J Clin Oncol, 25(33): 5172-9. [Abstract] [Full-text]
12. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.
    J Clin Oncol, 25(33): 5165-71. [Abstract] [Full-text]
13. Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO.
    Cancer Chemother Pharmacol, 61(2): 243-50. [Abstract] [Full-text]
14. Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells.
    Cancer Immunol Immunother, 57(2): 247-63. [Abstract] [Full-text]
15. New T cell epitopes identified from an anti-idiotypic antibody mimicking ovarian cancer associated antigen.
    Cancer Immunol Immunother, 57(2): 143-54. [Abstract] [Full-text]
16. Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125.
    J Natl Cancer Inst, 99(22): 1706-14. [Abstract] [Full-text]
17. Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells.
    Int J Cancer, 122(2): 274-80. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.